Health Canada Approves TEVIMBRA® (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma is a rare and debilitating disease with limited effective treatment options currently available to Canadian patients Approval supported by results of the RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival BeOne Medicines, a global oncology company, today announced that Health Canada has granted a Notice of Compliance (NOC), approving TEVIMBRA® (tislelizumab for […]